By using defined ABC DLBCL cell lines, we evaluated the advantages of combinatorial treatment with the irreversible BTK inhibitor Ibrutinib and the allosteric MALT1 inhibitor S-Mepazine. The gene discussed is MALT1; the disease is aneurysmal bone cyst.